Overview of the extranigral aspects of parkinson disease

Archives of Neurology

Volumn 66, Issue 2, 2009, Pages 167-172

  Lim, Shen Yang ^a   Fox, Susan H ^a   Lang, Anthony E ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; DOPA; LEVODOPA;

ANATOMY; BIOCHEMISTRY; CLINICAL FEATURE; DEMENTIA; DISEASE CLASSIFICATION; HUMAN; MOTOR DYSFUNCTION; NEUROPROTECTION; PARKINSON DISEASE; PATHOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYMPTOM; VISUAL HALLUCINATION;

ANTIPARKINSON AGENTS; AUTONOMIC NERVOUS SYSTEM DISEASES; BRAIN; DISEASE PROGRESSION; HUMANS; LEWY BODIES; NERVE DEGENERATION; NEURAL PATHWAYS; NEURONS; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE;

EID: 60549085946     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2008.561     Document Type: Review

References (35)

1. 11C-WeregAY 100635 PET study. Neurology. 2003;60(4):601-605.
2. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24(2):197-211.
3. Dickson DW, Fujishiro H, DelleDonne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 2008;116 (1):125-128.
4. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol. 2008;63(2):167-173.
5. Ross GW, Abbott RD, Petrovitch H, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord. 2006;21(12):2062- 2067.
6. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology. 1996;46(2):388-393.
7. Stiasny-Kolster K, DoerrY, Möller JC, et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain. 2005;128(pt1):126-137.doi:10.1093/brain/awj322.
8. Boeve BF, Dickson DW, Olson EJ, et al. Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med. 2007;8(1):60-64.
9. Uchiyama M, Isse K, Tanaka K, et al. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology. 1995;45(4):709-712.
10. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology. 2006;66(6):845-851.
11. Abbott RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology. 2005;65(9):1442-1446.
12. Schuurman AG, van den Akker M, Ensinck KTJL, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology. 2002; 58(10):1501-1504.
13. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord. 2000;15(4):669-677.
14. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology. 2001;57(3):456-462.
15. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord. 2007;22(11):1581-1586.
16. Gao X, Chen H, Schwarzschild MA, et al. Erectile function and risk of Parkinson's disease. Am J Epidemiol. 2007;166(12):1446-1450.
17. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system [published online February 16, 2005]. Brain. 2005;128(6):1314-1322. doi: 10.1093 /brain/awh445.
18. Fumimura Y, Ikemura M, Saito Y, et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in Lewy body disease. Neuropathol Exp Neurol. 2007;66(5):354-362.
19. Cools R. Dopaminergic modulation of cognitive function-implications for L-dopa treatment in Parkinson's disease. Neurosci Biobehav Rev. 2006;30(1):1-23.
20. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. 2006;59(5):852-858.
21. Black KJ, Hershey T, Hartlein JM, Carl JL, Perlmutter JS. Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease. Neuropsychopharmacology. 2005;30:590-601.
22. Clissold BG, McColl CD, Reardon KR, Shiff M, Kempster PA. Longitudinal study of the motor response to levodopa in Parkinson's disease. Mov Disord. 2006; 21(12):2116-2121.
23. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord. 2006;21(8):1123-1130.
24. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol. 2005;4(10):605-610.
25. Braak H, Rub U, Jansen Steur ENH, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology. 2005; 64(8):1404-1410.
26. Colosimo C, Hughes AJ, Kilford L, Lees AJ. Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003;74(7):852-856.
27. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Ann Neurol. 2003;60:1745-1748.
28. Poewe W. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov Disord. 2005;20(suppl 12):S77-S82.
29. Levy G. The relationship of Parkinson disease with aging. Arch Neurol. 2007;64 (9):1242-1246.
30. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125(pt 2):391-403. doi:10.1093/brain/awf033.
31. Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005;64(1):81-86.
32. Cheng AVT, Ferrier IN, Morris CM, et al. Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. J Neurol Sci. 1991; 106(1):50-55.
33. Mori F, Tanji K, Zhang H, Kakita A, Takahashi H, Wakabayashi K. a-Synuclein pathology in the neostriatum in Parkinson's disease. Acta Neuropathol. 2008;115(4):453-459.
34. Joyce JN, Ryoo HL, Beach TB, et al. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res. 2002;955(1-2):138-152.
35. Halliday GM, Macdonald V, Henderson JM. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain. 2005;128(pt 10):2272-2280. doi:10.1093/brain /awh596.